APELLIS PHARMACEUTICAL

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference

21 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

04 Nov 2023 13:37:55 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

01 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

25 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

20 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

05 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

02 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023

25 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

29 Aug 2023 06:58:00 By Nasdaq GlobeNewswire

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

22 Aug 2023 16:43:29 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

31 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

30 Jul 2023 13:00:40 By Nasdaq GlobeNewswire

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

29 Jul 2023 14:52:12 By Nasdaq GlobeNewswire